Your session is about to expire
← Back to Search
Study Summary
This trial tests a new drug to see if it reduces psoriasis skin plaques, compared to an approved drug and placebo. Participants will be monitored for up to 69 weeks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 20 Patients • NCT03000309Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
What is the total number of participants signed up to partake in this experiment?
"Affirmative. According to information from clinicaltrials.gov, this study is currently recruiting patients and was first posted on November 6th 2023 with its most recent update occurring on the 21st of November. The research requires 1000 participants at a single site to complete the trial."
Are new participants currently being accepted for this investigation?
"Indeed, the information posted on clinicaltrials.gov attests to this trial's active recruitment status. It was initially added on November 6th 2023 and has since been amended once more as of November 21st 2023. The researchers aim to recruit 1000 volunteers from a single medical facility."
Has the FDA sanctioned TAK-279 for therapeutic implementation?
"Our team at Power deems the safety of TAK-279 to be a 3, as clinical trials have demonstrated both efficacy and numerous rounds of data supporting its safety."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Noble Clinical Research: < 24 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger